Form 4: Pulse Biosciences Director Acquires Shares in Open Market Transaction

Robert W. Duggan, a director at Pulse Biosciences, purchased 45,404 shares of common stock at a weighted average price of $17.13 on December 12, 2024.

Summary

• Robert W. Duggan, a director of Pulse Biosciences, acquired 45,404 shares of common stock on December 12, 2024.
• The shares were purchased at a volume-weighted average price of $17.13 per share.
• Following the transaction, Mr. Duggan directly owns 42,273,461 shares of Pulse Biosciences common stock.
• He also indirectly owns 561,089 shares through Genius 24C Inc. and 400,877 shares through Blazon Corporation, both entities of which he is the sole shareholder.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the director's purchase suggests confidence in the company, but it's a routine transaction.

Positives

• The director's purchase of shares indicates confidence in the company's future prospects.
• The purchase increases the director's stake in the company, aligning his interests with other shareholders.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the trading activities of company directors and officers.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The transaction is typical for a director increasing their stake in the company, similar to other insider transactions in the biotech sector.

Stakeholder Impact

• The purchase may positively influence investor confidence in the company.
• The increased stake of a director aligns his interests with those of other shareholders.

Key Dates

Keywords

Pulse Biosciences, insider trading, stock purchase, Robert W. Duggan, director, share acquisition, PLES